fda stop compounding semaglutide Novo asks to bar compounders from making copies New Novo Nordisk initiatives support

[10] The drug is not yet approved by the Food and Drug Administration (FDA), which means it cannot be legally prescribed for everyday use in the United States as of 2026

Moreover, Noom has shown these habits can drive health outcomes both on their own and alongside medication

Nausea, reduced appetite, and burping occur commonly with subcutaneous injections too, especially during the first few weeks of treatment or after a dose increase

Palmer BF

Side effects are generally mild, such as nausea, diarrhea, or digestive discomfort

This pricing structure ensures that as your healthcare provider adjusts your dose upwarda normal part of GLP-1 therapyyou won't face unexpected bill increases